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Abstract:
Treatment of pancreatic cancer that cannot be surgically resected currently relies on minimally beneficial cytotoxic chemotherapy with gemcitabine. As the 4 th leading cause of cancer death in the United States with dismal survival statistics, pancreatic cancer demands new and more effective treatment approaches. Resistance to gemcitabine is nearly universal and appears to involve defects in the intrinsic/mitochondrial apoptotic pathway. The bioactive sphingolipid ceramide is a critical mediator of apoptosis initiated by a number of therapeutic modalities.
Interestingly, insufficient ceramide accumulation has been linked to gemcitabine resistance in multiple cancer types, including pancreatic. Taking advantage of the fact that cancer cells frequently have more negatively charged mitochondria, we investigated a means to circumvent resistance to gemcitabine by targeting delivery of a cationic ceramide (L-t-C6-CCPS; LCL124)
to cancer cell mitochondria. LCL124 was effective in initiating apoptosis by causing mitochondrial depolarization in pancreatic cancer cells but demonstrated significantly less activity against nonmalignant pancreatic ductal epithelial cells. Furthermore, we demonstrate that the mitochondrial membrane potentials of the cancer cells were more negative than nonmalignant cells, and that dissipation of this potential abrogated cell killing by LCL124, establishing that the effectiveness of this compound is potential-dependent. LCL124 selectively accumulated in and inhibited the growth of xenografts in vivo, confirming the tumor selectivity and therapeutic potential of cationic ceramides in pancreatic cancer. Interestingly, gemcitabine resistant pancreatic cancer cells became more sensitive to subsequent treatment with LCL124, suggesting that this compound may be a uniquely suited to overcome gemcitabine resistance in pancreatic cancer.
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Introduction:
Pancreatic tumors are notoriously treatment-resistant (Jaffee et al., 2002) , and pancreatic cancer is predicted to affect 43,920 patients and cause 37,390 deaths in 2012 (cancer.gov) making it the fourth leading cause of cancer death in the United States. Gemcitabine (GMZ) has been the standard treatment for advanced pancreatic cancer for the past decade (Rao and Cunningham, 2002; Van Cutsem et al., 2004 ) based on marginal improvement in disease-related symptoms and minimal survival benefit over 5-FU (5.6 vs. 4.4 months), however resistance develops rapidly in almost all patients (Burris et al., 1997) . Recently a regimen consisting of oxaliplatin, irinotecan, fluorouracil, and leucovorin (FOLFIRINOX) was compared with GMZ, resulting in an overall survival of 11.1 months vs. 6.8 with GMZ. Unfortunately, this regimen represents only a marginal improvement as it improved survival but increased toxicity versus GMZ in the phase III trial (Conroy et al., 2011 ).
Cancer cells have been shown to have a shift in the balance between pro-apoptotic ceramide and anti-apoptotic sphingosine 1-phosphate (S1P), often favoring production of oncogenic S1P. This phenomenon is associated with cancer progression and poor therapeutic outcomes (Ogretmen and Hannun, 2004; Liu et al., 2009; Beckham et al., 2010) . Similar to other cancers, dysregulation of sphingolipid metabolism has been observed in pancreatic cancer (Yu et al., 2003) . Further studies suggest that ceramide generation and accumulation is a critical determinant of pancreatic cancer cell apoptosis in response to cytotoxic agents including GMZ (Modrak et al., 2004; Modrak et al., 2009) . Similarly, enhanced expression of enzymes involved in the catabolism of ceramide (and, frequently, production of S1P) contributes to drug resistance in pancreatic cancer (Modrak et al., 2006) . In another study, response to treatment of the ceramide/S1P ratio was correlated with the sensitivity and, conversely, the resistance of JPET #199216
pancreatic cancer cells to GMZ (Guillermet-Guibert et al., 2009) . Whereas cell lines with a low ceramide/S1P ratio required high concentrations of GMZ to induce apoptosis, cell lines with more favorable ceramide/S1P ratios were up to 10-fold more sensitive. Significantly, it was
shown that Bcl-xl and inhibition of the mitochondrial apoptosis pathway played a primary role in resistance to GMZ-induced pancreatic cell apoptosis (Schniewind et al., 2004) . These data suggest that mitochondrial apoptosis and a favorable sphingolipid response to treatment are necessary components of GMZ-induced cell death in pancreatic cancer. Furthermore these data highlight the potential of manipulating these pathways to overcome the resistance of pancreatic cancer to current therapy.
The cationic ceramides (L-t-ω-pyridinium Cn-ceramide, generally termed Cn-CCPS) were designed to preferentially localize into negatively charged intracellular compartments due to the positive charge created by the pyridinium ring . Many types of cancer cells have more negatively charged mitochondria (Chen, 1988; Modica-Napolitano and Aprille, 2001) compared to normal cells. It is reasonable to predict that cationic ceramides would preferentially accumulate in the mitochondria of cancer cells based on their increased negative charge. Indeed, the efficacy of cationic ceramides on tumor regression has been confirmed in multiple tumor models (Novgorodov et al., 2005; Senkal et al., 2006; Dahm et al., 2008) . Specifically, LCL29
and 124 (D-e-and L-t-stereoisomers of C6-CCPS) (Senkal et al., 2006; Szulc et al., 2006) have been shown to have anti-proliferative effects in MCF7 and HNSCC cell lines (Rossi et al., 2005) .
The synergistic effects of LCL124 in combination with GMZ on the inhibition of cell growth were also demonstrated in HNSCC cells in vitro (Rossi et al., 2005) , and on HNSCC tumors in vivo (Senkal et al., 2006 
MTS Cytotoxicity assays
Cell viability was assessed using the CellTiter 96 Aqueous One Solution Cell Proliferation Assay Kit (Promega; Madison, WI, USA). Cells were plated at 5 x10^3 cells per well in 96-well plates and incubated overnight. The following day, media were replaced with desired treatment and after incubation the assay was carried out according to the manufacturer's instructions. EC50
was calculated using Prism 4 software. For experiments using inhibitors, cells were pretreated with inhibitors for 1 h (FCCP for 15 minutes) at 37°C before adding media containing vehicle or LCL124. The remainder of the assay was carried out as described above.
Mitochondrial fractionation
5x10^6 cells were seeded per 150mm dish. Treatment was initiated when cells reached 90%
confluence, and cells were collected at the indicated times. Cell fractionation was performed using the Mitochondrial Fractionation Kit (Active Motif North America, Carlsbad, CA, USA) according to manufacturer's instructions and the purity of the fractions was examined by western blot using GAPDH and cytochrome c. (Lemasters and Ramshesh, 2007) .
Western blotting
Measurement of mitochondrial membrane depolarization by JC-1 staining
Mitochondrial membrane potential (ΔΨm) was measured qualitatively using the lipophilic fluorescent probe 5,5′,6,6′-tetrachloro-1,1′,3,3′-tetraethylbenzimidazol-carbocyanine iodide (JC-1, Cayman Chemicals, Michigan, USA). 8x10 5 Aspc-1 and MIA cells were plated on 60mm dishes. 
Measurements of Oxygen consumption
Oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) were measured in real-time using a Seahorse Bioscience XF24 extracellular flux analyzer (Seahorse Bioscience, North Billerica, MA, USA) as previous described (Beeson et al., 2010 Following an overnight incubation, assays were initiated by replacing the growth medium with 800 µl of assay medium (50:50 mixture of Dulbecco's modified Eagle's essential medium and
Ham's F12 nutrient mix without phenol red supplemented with 15 mM NaHCO 3 , 0.2 mM glycine, and 6 mM sodium lactate). After establishing baseline OCRs, LCL124 was introduced at injection A and measurements continued for 90 min. Additional measurements were performed after injection of rotenone (final concentration 1 μ M) at injection B. For any one treatment, the rates from three or four wells were used.
HPLC-MS/MS analysis
Analyses of sphingolipid species and test compound were performed by the MUSC Lipidomics Shared Resources on a Thermo Finnigan TSQ 7000, triple-stage quadrupole mass spectrometer operating in a Multiple Reaction Monitoring positive ionization mode as described . Briefly, samples were fortified with internal standards and extracted into a one-phase solvent system with ethyl acetate/isopropanol/water (60:30:10%, v/v). 4 ml was separated followed by evaporation under nitrogen. After reconstitution in 100 μ l of acidified (0.2% formic acid) methanol, samples were injected on the HP1100/TSQ 7000 LC/MS system and gradienteluted from the BDS Hypersil C8, 150×3.2 mm, 3 μ m particle size column, with 1.0 mM methanolic ammonium formate/2 mM aqueous ammonium formate mobile phase system. Peaks corresponding to the target analytes and IS were collected and processed using the Xcalibur software.
Tumor xenografts
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with a as the smallest diameter and b as the largest, if depth is not measurable.
After tumors reached an average volume of at least 100 mm 3 , animals were treated every other day for 2 weeks with PBS and LCL124 (40 mg/kg) via intraperitoneal injection. Animals were weighed two times per week and tumor size was evaluated by digital caliper measurements.
MALDI-MS Tissue Imaging
Tissue sections from LCL124 treated and untreated xenograft tumors (10 μ m thick) were cut on a cryostat (Thermo Microm HM550), thaw mounted on Bruker ITO conductive slides, washed with 100 mM ammonium acetate, and placed in a vacuum dessicator for five minutes prior to matrix application. Tissue slices were coated with 2, 5-dihydroxybenzoic acid (DHB) matrix at 30mg/ml in 50% methanol and 1% TFA using an Image Prep (Bruker Daltronics). ImagePrep matrix thickness was closely monitored and tailored to our matrix of choice. Post matrix application and prior to MS analysis the the slides were placed in the dessicator for 15 minutes. acetonitrile, and direct injection via electrospray into the FT.
Statistical Analysis
Statistical analyses were performed by one-way ANOVA and unpaired one-tailed t test, using Prism (version 4.0) from GraphPad. The level of significance was set at **, < 0.01 and *, < 0.05 in figures. p<0.05 was considered significant.
Results:
Induction of apoptosis is generally divided into the extrinsic death receptor pathway and the intrinsic mitochondrial pathway with the later accounting for most chemotherapy-induced apoptosis. One mechanism of GMZ-induced apoptosis requires activation of the intrinsic pathway with depolarization of the inner mitochondrial transmembrane potential (ΔΨm) with concomitant release of cytochrome c and activation of downstream executioner caspases.
Development of an impaired intrinsic apoptotic pathway in tumors results in resistance to GMZ and ultimately unsuccessful management of pancreatic cancer (Friess et al., 1998; Xu et al., 2002; Schniewind et al., 2004) . In order to improve therapeutic efficacy to pancreatic cancer, a group of drugs was designed to bypass upstream GMZ resistance by directly targeting mitochondria.
Three candidate compounds that differ by the length of their N-acyl-chain (LCL124: C6-CCPS, LCL89: C12-CCPS and LCL87: C16-CCPS, previously described ) were tested in this study.
This article has not been copyedited and formatted. The final version may differ from this version. Figure 1A ) and Aspc-1 cells were the most sensitive to LCL89 (EC50 10.80µM, Figure 1B ). Toxicity from chemotherapy is frequently attributable to its lack of tumor specificity, making tumor-targeted delivery of anticancer drugs one of the most important steps for the development of chemotherapeutic agents. As cationic ceramides are designed to target more negatively charged mitochondria in tumor cells, we aimed to test their tumor selectivity by using the immortalized normal pancreatic cell line DT-PD59. As shown in Figure 1C , while DT-PD59 cells exhibited greater EC50 to LCL124 (EC50 62.75µM), which indicated a wider selectivity window particularly against cancer cell lines compared with normal cells, the EC50s of DT-PD59 to LCL89 and LCL87 (14.76 and 9.511 µM, respectively) were nearly equivalent to their EC50s in tumor cells (MIA: 9.993 and 10.69 µM, respectively. Aspc-1: 10.80 and 23.68 µM, respectively). It is of note that there was no apparent dose response when cells were treated using LCL89 and LCL87 in comparison to LCL124, potentially due to their poor solubility. In fact, LCL124 is readily soluble in water, whereas the other two compounds required an organic cosolvent. These data led us to choose LCL124 as our lead compound for further study. variation of response to C6-ceramide in these cells likely due to differences in expression, regulation, and functionality of apoptosis effectors. Interestingly, there was a much narrower range of sensitivity to LCL124 with MIA being the most sensitive and Aspc-1 being the least.
The sensitivity to LCL124 is substantially higher than to the non-modified C6-ceramide suggesting increased potency and uniform responsiveness to LCL124 regardless of existing defects in death pathways.
LCL124 accumulates in mitochondria and disrupts cellular respiration. To examine the intracellular distribution of LCL124, Aspc-1 and Panc02 pancreatic cells were treated with 20 µM LCL124 for 24 hours. Cells were then fractionated into mitochondrial, cytosolic and nuclear compartments with purity assessed by presence and absence of cytochrome c, GAPDH, and lamin B ( Figure 2B ). Fractions were then analyzed for LCL124. As evidenced in Figure 2A , the mitochondrial compartment accumulated substantially more LCL124 than the nucleus or cytoplasm. At 24 hours, the nuclear compartment, which has a slight negative charge (Aronov et al., 2004) , was also accumulating drug but only at half the concentration of that in the mitochondria. A similar result was observed in Panc02 cells (Suppl. 1A), in which we also observed accumulation of endogenous total ceramide in the cell mitochondria, whereas total cellular ceramide did not change appreciably (Suppl. 1B). In order to determine whether LCL124 is metabolized by endogenous enzymes, we treated cells with 17-Carbon LCL124 (vs.
endogenous sphingosine which has 18 Carbons) and measured C17-sphingolipid species from 15 minutes to 24 hours after treatment. Interestingly, LCL124 progressively accumulated inside the cells as expected, but no C17 metabolites were detected in cells or in the medium (Suppl. 1 C).
Thus, we conclude that LCL124 is not metabolized by cancer cell enzymes.
This article has not been copyedited and formatted. The final version may differ from this version. Although cancer cells frequently utilize glycolysis for ATP production (Dang, 2010) , functional mitochondria appear to be crucial for cancer cell survival, and disruption of mitochondrial function has been suggested as a potential avenue for cancer therapy (Pilkington et al., 2008) .
Here, we proceeded to determine the effect of LCL124 treatment on mitochondrial bioenergetics (oxygen consumption (OCR) and extracellular acidification (ECAR)) using MIA, Aspc-1, and DT-PD59 cells. We first observed that basal OCR was approximately two-fold higher in MIA and Aspc-1 cancer cell lines when compared to DT-PD59 normal cells (data not shown), which
indicates that the mitochondria in cancer cells are more metabolically active than the mitochondria in normal cells. Furthermore, the drop of OCR in the presence of LCL124 is consistent with LCL124 targeting mitochondria and thereby disrupting aerobic respiration. As shown in Figure 2C and 2D, OCR decreased in a dose-dependent manner within 30 minutes following administration of LCL124 in both Aspc-1 and MIA cells.
LCL124 causes mitochondrial depolarization and apoptosis in pancreatic cancer cells.
Based on the believed mechanism of action of this class of drugs 
LCL124-induced cell killing is dependent on mitochondrial membrane potential.
Tumor cells have been reported to have more negatively charged mitochondria (Chen, 1988) , resulting in our hypothesis that they should be more sensitive to cationic LCL124. In order to examine whether the sensitivity to LCL124 is associated with Importantly, mitochondrial LCL124 in MIA cells is 1.5 fold higher (6643.7± 897pmole/500ug protein) than that in the whole cells (4298 ± 641.9 pmole/500ug protein), suggesting LCL124 has a preference to accumulate in the mitochondria of cancer cells.
Next, to evaluate whether increase drug uptake leads to LCL124 sensitivity in cancer cells, we 
Induction of GMZ resistance in pancreatic cells sensitizes them to LCL124. Since it was
previously reported that LCL124 acted in synergy with GMZ to kill squamous carcinoma of the head and neck (Senkal et al., 2006) , a similar experiment was carried out in Panc-02 cells. No synergy was observed when GMZ and LCL124 were combined, or when GMZ was given 2 hours prior to LCL124 treatment (Supp 4A and 4B). To our surprise, cells selected to become GMZ resistant (Supp 4C), as described previously (Shi et al., 2002) , became 2.5-fold more sensitive to LCL124 ( Figure 5A ). Interestingly these same GMZ resistant cells were not more sensitive to 5-FU, cisplatin, etoposide or doxorubicin ( Figure 5B ) suggesting that GMZ-induced sensitivity to LCL124 was specific. To explore if GMZ resistance resulted in increased drug uptake, levels of LCL124 were determined in both wild type cells and in GMZ resistance cell. 
LCL124 inhibits pancreatic cancer xenograft growth and enhances animal survival in vivo.
In preparation for evaluating the in vivo anti-tumor activity of the compound on tumor cell xenograft growth in nude mice, LCL124 was injected at 20, 40, or 80 mg/kg doses and blood chemistry was analyzed seven days post injection to determine toxicity (Suppl. 5). Based on these data it was determined that 40 mg/kg did not significantly alter blood chemistry, and this dose was chosen for administration to mice bearing Aspc-1 xenografts. As can be seen in Figure   6 , LCL124 effectively inhibited tumor growth. At 40 mg/kg once every other day administration for 15 days, LCL124 inhibited tumor growth by 50% in Aspc-1 xenografts compared with the vehicle-treated group ( Figure 6A) . Importantly, the survival curve demonstrates that there is an advantage to the animal based on treatment with LCL124. LCL124 treatment significantly increases survival compared to untreated animals ( Figure 6B ). There was no observed weight loss in LCL124 treated animals over this time period (Suppl. 6B).
To examine whether LCL124 preferentially accumulates in tumor tissues, the distribution of LCL124 after multiple treatment was analyzed by mass spectrometry in mice bearing tumor This article has not been copyedited and formatted. The final version may differ from this version. xenografts. Consistent with what we have seen in our clearance study, LCL124 levels were high in the kidney suggesting that kidneys may be the main organ for clearance. Remarkably, the level of LCL124 in tumor tissues was approximately 500 pmole/mg protein which was much higher than liver, spleen, brain, intestine and lung (all <110 pmole/mg) revealing a significant increase uptake of LCL124 in tumor tissue. Although the heart is known to be enriched in mitochondria, accumulation in this organ was 10 fold less than in the tumor ( Figure 6C ). Tumor tissues were directly analyzed by MALDI mass spectrometry imaging (Cornett et al., 2008; Nilsson et al., 2010) for the presence and distribution of LCL124. The spatial distribution of the 475.4 m/z LCL124 in tumor tissue is shown in Figure 6D and was readily detectable. There was no ion detected at this mass in untreated tumor tissues ( Figure 6E ). The drug could also be detected in kidney tissues of LCL124 treated animals (data not shown). Confirmation that this 475.4 m/z ion in tissues is LCL124 was done by isolation and collision-induced fragmentation (Suppl, 6C-E). Analysis of the effect of LCL124 on endogenous level of sphingolipids in kidney and tumor, the two organs that demonstrated accumulation of LCL124, showed that both organs had significant increased total ceramide levels ( Figure 6F ), however different ceramide species were altered with long chain ceramides (C-14, C-16, and C-18) elevated in tumors and very long chain ceramide C-26 elevated in the kidney (Suppl. 6A). Tumor tissues also demonstrated a greater elevation in sphingosine levels in response to LCL124, however, there was no significant change detected in S1P ( Figure 6F ).
Discussion:
The drug-resistant and rapidly progressing nature of pancreatic cancer benchmark the need for with numerous agents with uniformly disappointing results (Rao and Cunningham, 2002; Van Cutsem et al., 2004; Oberstein and Saif, 2011) . A recent trial of FOLFIRINOX verses GMZ did exhibit an improvement in progression-free survival (Conroy et al., 2011) . Unfortunately, FOLFIRINOX, itself a combination of several toxic agents, reduced overall quality of life, a critically important parameter for patients undergoing palliative treatment for advanced cancer.
Recent studies have demonstrated that resistance to GMZ is mainly attributed to an altered intrinsic apoptotic threshold suggesting an essential role for the mitochondrial compartment in pancreatic cancer cell death (Schniewind et al., 2004) . Although abnormalities in ceramidemediated cell death have been studied in multiple models including pancreatic cancer (Modrak et al., 2004; Ogretmen and Hannun, 2004; Modrak et al., 2006; Guillermet-Guibert et al., 2009 ), sphingolipid metabolism has been inadequately explored as an avenue for pancreatic cancer therapy. Exogenous ceramides induce apoptosis primarily through the mitochondrial pathway with activation of the caspase 9-3/7 executioner mechanism (Lin et al., 2005; Lin et al., 2007; Yu et al., 2010) . Ceramide accumulation is a hallmark of multiple modalities of apoptosis-inducing cancer therapies (Huwiler and Zangemeister-Wittke, 2007) . Likewise, resistance to therapy has been linked to lack of ceramide accumulation, by reduced generation (Chmura et al., 1997; Holland et al., 2007) and by accelerated metabolism Liu et al., 2009) . Despite the favorable signaling responses elicited in vitro, treating patients with exogenous ceramides presents major challenges: (a) poor water solubility and cellular uptake, (b) intracellular metabolism, and (c) lack of tumor-targeted delivery. Taking advantage of the fact that mitochondria in cancer cells are typically more negatively charged than in normal cells, novel ceramide analogs have been developed with greater water solubility, cell-membrane permeability, and cellular uptake profiles in comparison to native ceramides . LCL124
This article has not been copyedited and formatted. The final version may differ from this version. belongs to a group of ceramide analogs with a fixed positive charge that targets them to negatively charged organelles, predominantly mitochondria (Senkal et al., 2006) . We examined LCL124, LCL89, and LCL87 in pancreatic cancer and in immortalized pancreatic cells. These studies show that LCL124 is the most efficacious compound for killing cancer cells regardless of their pre-existing defects in death inducing pathway and is relatively nontoxic to normal cells. This is consistent with a previous study where keratinocytes demonstrated less sensitivity to LCL124 compared to HNSCC cells, making this drug appear preferentially capable of inducing cell death in tumors (Senkal et al., 2006) . In addition, compared to LCL89 and LCL87, LCL124 demonstrated more solubility in aqueous solutions, which will aid in formulation and delivery to patients.
LCL124 selectively targets to mitochondria due to the affinity of the cationic pyridinium moiety Figure 4A ). We also observed markedly amplified but poorly organized mitochondria in these two cancer cell lines which is also frequently seen in transformed cells (Han et al., 2002; Lee and Wei, 2005; Kim and Dang, 2006) . LCL124 also accumulated in the kidney, suggesting renal clearance. Interestingly, in tumors we observed increases in long chain ceramides (C-14, C-16, and C-18) which have been identified as pro-apoptotic , while kidney had a substantial increased in a very long chain ceramide (C-26), which has been shown to have anti-apoptotic roles ) (Suppl. 6A).
Given that mitochondria account for the majority of cellular oxygen consumption, OCR serves as a direct indicator of mitochondrial function (Hussain et al., 2008) . In this study we were able to determine that LCL124 affected oxygen consumption in pancreatic cells. As expected we also demonstrated that untreated cancer cells had significantly higher OCR and ECAR relative to normal cells reflecting increased metabolism and mitochondrial function. Mitochondrial depolarization is a hallmark of apoptosis, reflecting increased membrane permeability resulting in cytochrome c release and activation of the downstream caspase cascade.
We utilized JC-1, a cationic dye which forms fluorescent aggregates in proportion to the integrity of the mitochondrial membrane, to analyze the impact of LCL124 on mitochondrial membrane depolarization. Similar to ceramide treated cells (Arora et al., 1997; Novgorodov et al., 2005; Stoica et al., 2005) treatment with LCL124 promoted an increase in the ratio of fluorescence at 530/590nm indicating that LCL124 caused mitochondrial depolarization, a hallmark of intrinsic apoptosis. Cells treated with GMZ did not exhibit alterations in JC-1 staining, indicating that GMZ did not promote mitochondrial depolarization in these models ( Figure 3A and B). As such, LCL124 may be able to cause tumor cell death in drug resistant cells since it bypasses the upstream mechanisms of resistance that impair induction of intrinsic apoptosis (Bold et al., 1999; Bai et al., 2005) and functions directly at the mitochondria to induce mitochondrial membrane depolarization leading to reactivation of intrinsic apoptosis. Importantly, our data demonstrated that LCL124 is not metabolized by cancer cell enzymes (Suppl. 1C), but appears to elevate endogenous ceramide, specifically in the mitochondria (Suppl. 1A and B), as part of its cell killing mechanism.
Interestingly, we observed increased sensitivity to LCL124 in GMZ resistant pancreatic cancer cells, cells that did not show increased sensitivity to other cytotoxic chemotherapy drugs ( Figure   5A and B) suggesting a specific mechanism of sensitivity to LCL124 might be induced by GMZ.
GMZ can be phosphorylated and incorporated into mitochondrial DNA (mt-DNA), interfering with mt-DNA replication (Zhu et al., 2000; Mini et al., 2006; Fowler et al., 2008 Figure 5C ). We observed an increase in the total amount of mitochondria 
